09Jun

SpeeDx and Cepheid Announce Partnership on European Distribution

SYDNEY, AUSTRALIA -- 05/06/17 -- SpeeDx Pty, Ltd. today announced an agreement with Cepheid for distribution of its PlexPCRTM and ResistancePlusTM molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.

The timing of the agreement coincides with recent guideline changes across Europe recommending M. genitalium resistance screening in the management of non-gonococcal urethritis.1 The inclusion of a macrolide resistance test when detecting M. genitalium provides clinicians with much needed information to guide antibiotic treatment. Resistance to frontline antibiotic treatment is increasing and has been observed in up to 50 % of M. genitalium positive patients in recent studies.2

“This partnership is a true win-win,” said Colin Denver, CEO of SpeeDx. “We gain better access to these important European markets and Cepheid can bring its customers a comprehensive test for M. genitalium and azithromycin resistance.”

“SpeeDx offers a unique approach to simultaneous detection of pathogens and drug resistance directly from clinical specimens, consistent with Cepheid's approach to detecting tuberculosis,” said David H. Persing, MD, Ph.D., Cepheid’s Chief Medical and Technology Officer. "This technology could potentially be applied in multiple settings in which actionable treatment information is needed quickly."

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI M. genitalium (ResistancePlus™ MG) that combines detection of the disease with detection of markers for antibiotic resistance. For more information on about SpeeDx please see: http://www.speedx.com.au

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

1. Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis.

2. Unemo, M. & Jensen, J.S. ‘Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium’. 2016. Nat. Rev. Urol..268. Published online 10 Jan 2017. doi:10.1038/nrurol

Contacts for SpeeDx:

Europe:

Sarah Khan, PhD

+44.1480.405333

sarahk@kdm-communications.com

USA:

Rick Roose

CoActive Communications

+1 415.202.4445

rick@coactivepr.com

Australia:

Andrew Geddes

SeedMedia Pty Ltd.

+61(408)677.734

andrew@seedmedia.com.au

Contact for Cepheid:

Darwa Peterson

darwa@cepheid.com

Tel. + 1.408.400.4324

Related

North East Innovation Lab receives investment of £1.4m to continue vital work to protect health

The North East Innovation Lab, originally established as part of the region’s integrated Covid hub,...

Read More >

Radiometer helps enhance patient outcomes at the University of Leicester Hospitals NHS Trust

Crawley, UK – 15 February 2018 – Radiometer Ltd has implemented its AQURE Enterprise point-of-care...

Read More >

Entrust People and SCI Search & Selection rebrand to Entrust Resource Solutions

Following a year of strong growth and successful acquisitions, Entrust People and SCI Search & Selec...

Read More >

Press Release - RQM+ Appoints Life Science Executive Margaret Keegan as New CEO

RQM+, the world’s leading provider of regulatory, clinical and quality solutions to the MedTech ind...

Read More >

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share...

Read More >

Abingdon Health and DCN Diagnostics partner on commercialisation of AppDx m-Health technology

Abingdon Health and DCN Diagnostics have announced a commercial partnership to provide Abingdon Heal...

Read More >